New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
04:55 EDTFRX, FRX, FRX, JAZZ, JAZZ, JAZZ, TEVA, TEVA, TEVA, ADHD, ADHD, ADHD, SHPG, SHPG, SHPG, ABT, ABT, ABT, ALKS, ALKS, ALKS, AZN, AZN, AZN, ENVI, ENVI, ENVIAmerican Psychiatric Association holds annual meeting
167th Annual Meeting of the APA is being held in New York on May 3-7.
News For ADHD;SHPG;ABT;ALKS;AZN;ENVI;FRX;JAZZ;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 9, 2014
09:10 EDTAZNARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
08:31 EDTJAZZJazz, Concert say Phase 1 JZP-386 evaluation not done at highest dosage
Subscribe for More Information
08:02 EDTAZNMoventig approved in EU for opioid-induced constipation
Nektar (NKTR) reported partner AstraZeneca (AZN) announced that MOVENTIG has been granted Marketing Authorisation by the European Commission for the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative. MOVENTIG is the first once-daily oral peripherally-acting mu-opioid receptor antagonist to be approved in the European Union.
07:44 EDTAZN, TEVAAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
05:38 EDTSHPGShire downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
December 8, 2014
11:30 EDTTEVALeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
08:50 EDTALKSAlkermes price target raised to $63 on pipeline catalysts at Credit Suisse
Subscribe for More Information
08:21 EDTTEVAMerck says looked at all risks, including patent litgation, before Cubist deal
Subscribe for More Information
07:29 EDTJAZZUBS to hold investor trip
Subscribe for More Information
07:18 EDTJAZZUBS to hold investor trip
2014 Annual West Coast Investor Trip travels on the West Coast on December 8-10.
07:05 EDTAZNInnocoll appoints Tony Zook as CEO
Innocoll AG (INNL) announced that Tony Zook, formerly executive vice president, Global Commercial Operations, at AstraZeneca (AZN), has been appointed CEO effectively immediately. Michael Myers, will continue with the company as head of Portfolio Operations.
06:47 EDTTEVAArena says Teva files marketing authorization of Belviq in Israel
Arena Pharmaceuticals (ARNA) disclosed late Friday that Teva Pharmaceutical's (TEVA) local Israeli subsidiary, Abic Marketing Limited, has filed for marketing authorization of Belviq in Israel. In connection with the filing, Arena will receive a milestone payment of $250K.
December 5, 2014
13:41 EDTSHPGShire to host research and development day with a conference call hookup
Research and Development meeting to be held in New York on December 10 at 8 am. Webcast Link
10:35 EDTALKSHigh option volume stocks
High option volume stocks: NOAH FRAN BIG GREK KEY VIAB STRZ ALKS QTWW ONNN
09:49 EDTAZNUBS European pharmaceuticals analysts holds analyst/industry conference call
Subscribe for More Information
07:54 EDTTEVALannett names Michael Bogda as president, effective December 1
Subscribe for More Information
December 4, 2014
14:49 EDTSHPGSalix, Shire rise after analyst says merger would be 'attractive'
Subscribe for More Information
10:32 EDTTEVATeva receives positive outcomes in Europe for three-times-a-week COPAXONE
Teva Pharmaceutical Industries announced that it has received a positive outcome in the decentralized procedure for its new, three-times-a-week COPAXONE 40 mg/ml formulation for the treatment of adults with relapsing forms of multiple sclerosis RMS. The outcome follows a Positive Assessment Report from the United Kingdom, the Reference Member State’s Medicines and Healthcare Products Regulatory Agency, and all Concerned Member States in Europe who were involved in the procedure. Granting of national authorizations will happen in the near future. The three-times-a-week COPAXONE 40 mg/ml formulation will allow for an improved, less-frequent, subcutaneous dosing regimen for adults with RMS. The new formulation reduces the total number of injections by almost 60%, while maintaining the known benefits of once daily COPAXONE 20 mg/ml. “We welcome the opportunity to make COPAXONE 40 mg/ml available to patients with RMS in Europe,” said Rob Koremans, MD, President and CEO of Global Specialty Medicines at Teva. “Three-times-a-week COPAXONE 40 mg/ml will be available in Europe as early as the first quarter of 2015 with expected launches in Germany, Netherlands and Denmark. Launches in other EU countries are expected throughout 2015.”
08:45 EDTAZNAbbVie price target raised to $80 from $72 at Jefferies
Jefferies raised its price target for AbbVie shares to $80 while calling the company one of its top five global pharma picks for 2015. The firm's top U.S. pick is Pfizer (PFE) and its top Europe pick is Novartis (NVS). Bayer (BAYRY) and AstraZeneca (AZN) round out the top five. Jefferies thinks AbbVie's "strong momentum" will continue into the first half of 2015 and keeps a Buy rating on the name.
05:30 EDTTEVACTI BioPharma receives $15M payment from Teva for TRISENOX
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use